Althera announced the FDA approved its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of elevated LDL in adults with primary nonfamilial hyperlipidemia or homozygous familial ...

MORRISTOWN, N.J., March 31, 2021 /PRNewswire-PRWeb/ — Althera Pharmaceuticals, a company focused on heart health, today announced the FDA approval of Roszet (rosuvastatin and ezetimibe) tablets, as an ...

– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with ...

- NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins -- First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved -- Esperion’s ...

- NILEMDO ® (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients - - Bempedoic acid and ...

Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020. The Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . The FDA recently approved a therapy that combines rosuvastatin, a statin for LDL reduction, and ezetimibe, a ...

in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or 2 alone or in combination with other ...

On June 2, 2022, the US Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) issued an untitled letter [1] to Althera Pharmaceuticals, LLC (Althera) relating to promotional ...

ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 ...